Nanobody-engineered CLL-1 CAR T cells: A strategy for safer targeting in acute myeloid leukemia
Molecular Therapy Oncology · 2026-06 · 34 (2) · 201217
DOI: 10.1016/j.omton.2026.201217 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Oncology, 2026-06. Verfasst von Chakrapani Tripathi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sino-American Cancer Foundation, Covina, CA 91722, USA. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taipei Medical University.
Abstract (Originalsprache)
In our recent publication in Cancer Research Communications, “Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity,” we developed a next-generation nanobody-based chimeric antigen receptor (CAR) T platform targeting CLL-1 for acute myeloid leukemia (AML). Leveraging llama-derived single-domain antibodies (VHHs), we engineered highly specific CAR constructs against CLL-1 and CD33 and systematically evaluated their functional performance across in vitro and in vivo models.
Autor:innen und Institutionen
- Sino-American Cancer Foundation, Covina, CA 91722, USA.
Förderung
- Taipei Medical University
Zitieren
APA
Tripathi, C., Luh, F., & Yen, Y. (2026). Nanobody-engineered CLL-1 CAR T cells: A strategy for safer targeting in acute myeloid leukemia. Molecular Therapy Oncology, 34(2), 201217. https://doi.org/10.1016/j.omton.2026.201217
Vancouver
Tripathi C, Luh F, Yen Y. Nanobody-engineered CLL-1 CAR T cells: A strategy for safer targeting in acute myeloid leukemia. Molecular Therapy Oncology. 2026;34(2):201217. doi:10.1016/j.omton.2026.201217
BibTeX
@article{Tripathi2026,
author = {Tripathi, Chakrapani and Luh, Frank and Yen, Yun},
title = {Nanobody-engineered CLL-1 CAR T cells: A strategy for safer targeting in acute myeloid leukemia},
journal = {Molecular Therapy Oncology},
year = {2026},
volume = {34},
number = {2},
pages = {201217},
doi = {10.1016/j.omton.2026.201217}
}
EUVIMED